FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

172 letters match. Newest first.

  1. Daewoo Pharmaceutical Co., Ltd.

    FDA warns Daewoo Pharmaceutical over CGMP (manufacturing quality rules) failures at Busan plant; company suspended production.

    High risk
  2. Xtreme Tools International, Inc.

    FDA warned Xtreme Tools International after an inspection found manufacturing-rule failures for OTC topical drugs, including missing ingredient and batch testing.

    High risk
  3. Amish Origins Management, LLC

    FDA warned Amish Origins over manufacturing quality failures and unapproved or misbranded OTC pain relief and lip balm products.

    High risk
  4. DFI Co., Ltd.

    DFI Co., Ltd. of Gimhae, Korea, made CYBOW 11 urinalysis reagent strips under conditions FDA calls adulterated — complaint, nonconforming product, labeling and MDR failures.

    High risk
  5. Anti L’Age

    FDA warned Anti L'Age over dietary supplements made without required manufacturing standards, records, quality controls, and proper labeling.

    Medium
  6. Mother Earth Minerals, Inc.

    FDA warns Mother Earth Minerals that its Calcium, Magnesium and Silver are unapproved drugs with disease claims and lack quality controls.

    High risk
  7. Sedecal S.A.

    Sedecal S.A. warned for quality-system and reporting failures on mobile x-ray systems.

    High risk
  8. Shantou S.E.Z. Baojie Industry Co., Ltd.

    FDA warns Shantou S.E.Z. Baojie Industry over inadequate CGMP and component testing for OTC drug products, leading to Import Alert 66-40.

    High risk
  9. Taizhou Jingshang Cosmetics Technology Co., Ltd.

    FDA warns Taizhou Jingshang Cosmetics Technology over current good manufacturing practice failures in over-the-counter drugs, including missing identity tests for high-risk ingredients.

    High risk
  10. BioAsia Worldwide Sdn Bhd

    FDA warned BioAsia Worldwide over current good manufacturing practice violations for OTC drugs.

    High risk
  11. Cosco International, Inc.

    FDA warned Cosco International over nonprescription drug manufacturing failures and unapproved drug products.

    High risk
  12. Dyno Manufacturing, Inc.

    Dyno Manufacturing’s OTC hand sanitizer and antibacterial soap drugs lacked raw-material identity testing and other required manufacturing controls.

    High risk
  13. Nubratori, Inc. dba Nubratori Rx

    FDA cited Nubratori Rx, a sterile compounding outsourcing facility, for insanitary conditions and manufacturing quality failures that may contaminate its drug products.

    High risk
  14. Yangzhou Sion Commodity Co., Ltd.

    FDA warned Yangzhou Sion Commodity over drug manufacturing failures, including untested high-risk ingredients and unreliable lab records.

    High risk
  15. Dexcom, Inc.

    FDA warned Dexcom over quality-system and design-control failures for G6 and G7 glucose monitors, including an unapproved sensor component change.

    High risk
  16. Exer Labs, Inc.

    Exer Labs marketed its Exer Scan device for AI diagnosis and treatment without FDA approval or clearance and lacked quality procedures.

    High risk
  17. Neva Global Grup Sanayi Ic Ve Dis Ticaret Anonim Sirketi

    FDA warns Turkish OTC drug maker Neva Global over inadequate component testing, process validation, stability, and quality oversight.

    High risk
  18. International Laboratories Corp

    FDA warned International Laboratories Corp, a Thai drug manufacturer, over fabricated lab records and inadequate CGMP controls.

    High risk
  19. Vegewax Candleworx Ltd.

    FDA warns Vegewax Candleworx over CGMP violations in OTC drug manufacturing, including inadequate component testing and OOS investigations.

    High risk
  20. AmWiner & Raphe Holdings, LLC dba rapheGenerics Corp

    FDA cited rapheGenerics for manufacturing-quality failures and unapproved minoxidil hair regrowth drugs.

    High risk
  21. Shantou Kangjie Daily Chemical Industry Co., Ltd

    FDA warns Shantou Kangjie over CGMP failures for OTC drugs, including untested ethanol and no quality unit.

    High risk
  22. Western Innovations, Inc.

    FDA warns Western Innovations over manufacturing-rule violations in Acetyl-glutathione supplements after Denver inspection.

    Medium
  23. Randox Laboratories Limited

    FDA warned Randox Laboratories over inadequate risk analysis and corrective actions for carryover errors in RX series analyzers.

    High risk
  24. Viatris, Inc.

    FDA warns Viatris that its Indore, India, drug plant had unreliable quality data and weak investigations.

    High risk
  25. Akron Formulations India Private Limited

    Akron Formulations India's over-the-counter drugs are adulterated due to manufacturing quality (CGMP) failures, including unqualified active ingredient (API) suppliers and inadequate microbial testing.

    High risk
  26. Dr. Brite, LLC

    FDA cited Dr. Brite for manufacturing quality failures and selling unapproved, misbranded oral care and hand sanitizer drugs.

    High risk
  27. Guangzhou Four E’s Scientific Co., Ltd.

    FDA warns Guangzhou Four E’s over CGMP failures for OTC drugs, including a sterile-labeled product with inadequate sterility assurance.

    High risk
  28. Zhejiang Uniquality Nursing Products Technology Co., Ltd. dba ZheJiang YouQuan Care Products Technology Co., Ltd.

    FDA warns Zhejiang Uniquality over inadequate OTC drug component testing and quality oversight; import alert issued.

    High risk
  29. Unexo Lifesciences, Private Limited

    FDA warned Unexo Lifesciences over serious CGMP violations, including data integrity failures and torn batch records for U.S.-bound drugs.

    High risk
  30. Zhejiang Qimei Cosmetics Co., Ltd.

    Zhejiang Qimei Cosmetics drew an FDA warning for CGMP violations in sterile-labeled OTC isopropyl alcohol prep pads.

    High risk
  31. Analytical Food Laboratories, Inc.

    FDA warned contract testing lab Analytical Food Laboratories after inspection found unvalidated drug test methods and weak quality oversight.

    High risk
  32. Top Health Manufacturing, LLC

    Top Health Manufacturing's dietary supplements violated manufacturing and labeling rules, FDA says.

    Medium
  33. Argon Medical Productions & Vertrieb Gesellschaft MBH & CO

    FDA warns Argon Medical over dental implant quality-system failures, unreported injuries, and missing unique device identifier labeling.

    High risk
  34. MedOffice Saglik Endustri Anonim Sirketi

    FDA warned MedOffice Saglik after an inspection found missing batch release testing and inadequate process validation for over-the-counter drugs.

    High risk
  35. Choice All Natural, Inc. dba Om Botanical

    FDA warns Om Botanical of Apex, NC over filthy manufacturing, an unapproved rash cream, and lapsed FDA registration.

    High risk
  36. Soliteint Kozmetikai KFT

    Hungarian contract maker Soliteint Kozmetikai failed to test OTC pain-relief drugs and ingredients, FDA says; U.S. production halted.

    High risk
  37. Omni Lens Pvt. Ltd.

    FDA warns Omni Lens about CGMP failures and misbranding of ophthalmic OTC drugs made by unregistered contract manufacturers.

    High risk
  38. Outin Futures Corp.

    FDA warned Outin Futures, a Korean drug manufacturer, of CGMP violations and sunscreen misbranding after a March 2024 inspection.

    High risk
  39. Little Moon Essentials, LLC

    FDA warns Little Moon Essentials over CGMP failures and unapproved topical analgesic drugs made in Dania Beach, Florida.

    High risk
  40. Clean Solutions LLC

    FDA warned Clean Solutions LLC that its OTC hand soaps and sanitizer were adulterated because it released drugs without component or finished-product testing.

    High risk
  41. Restorative Botanicals, LLC

    FDA warns Restorative Botanicals over CGMP failures for two mushroom dietary supplements, including missing identity and toxic-element limits.

    Medium
  42. Aromas Para El Alma S.A.

    Aromas Para El Alma, a Costa Rica drug manufacturer, made EREWHON hand sanitizer/spray subpotent and broke manufacturing rules.

    High risk
  43. Greco Gas, Inc.

    Greco Gas, Inc. released medical gases without identity or purity testing and without quality oversight.

    High risk
  44. TJA Health, LLC

    FDA warns TJA Health LLC over unsafe drug manufacturing of toothpaste and mouth rinse due to untested components and poor quality control.

    High risk
  45. Orean Personal Care Ltd.

    FDA warned Orean Personal Care Ltd. that repeat manufacturing failures make its OTC drugs adulterated.

    High risk
  46. LS Promotions Inc.

    LS Promotions Inc. failed to adequately test and validate its OTC sunscreens, lip balm and hand sanitizer, making them adulterated drugs.

    High risk
  47. Txsyn Int. LLC

    FDA says Txsyn Int. repackaged dietary supplements without required manufacturing procedures and quality approval.

    Medium
  48. Guangzhou Baiyunshan Jingxiutang Pharmaceutical Co. Ltd.

    FDA warned Guangzhou Baiyunshan Jingxiutang Pharmaceutical over current good manufacturing practice violations in over-the-counter drug manufacturing, including inadequate specs and microbial testing.

    High risk
  49. Omega Tech Labs LLC

    Omega Tech Labs in Boise, Idaho, released microbially contaminated combination drug-device product and failed manufacturing rules.

    High risk
  50. West Coast Laboratories, Inc.

    FDA warned West Coast Laboratories over dietary supplements made without required manufacturing controls and illegally labeled.

    High risk